CRISPR Therapeutics AG - Common Shares (CRSP)
$44.51
2.06 (4.42%)
CRSP Stock Quote Delayed 30 Minutes
The 3 Best Cathie Wood Stocks to Buy in May 2024
Cathie Wood takes a very risky approach to investing, but she has plenty of great picks. Here are some of the best Cathie Wood stocks to buy.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
3.51B
PE Ratio
-10.23
EPS
-4.35
Volume (Avg. Vol.)
2.16M
Day's Range
$44.02 - $46.67
52-Week Range
$36.52 - $90.62
Dividend & Yield
N/A (N/A)
CRSP Stock Predictions, Articles, and CRISPR Therapeutics AG - Common Shares News
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
Discover these three biotech stocks set for major gains with groundbreaking health solutions. Invest in the future of medicine.
3 Biopharma Stocks Predicted to Soar in Q2 2024
These biopharma stocks can produce massive returns for Q2 based on new product releases and international treatment approvals.
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy.
